Your cart is currently empty!
Virafin (Interferon Alfa-2b) Injection
Generic brands for Interferon Alfa-2b Tablets Available in India Virafin 80mg Injection works by stimulating the immune system to attack and destroy cancer cells and viruses, and it can also help manage certain symptoms associated with viral infections. Brand Name Virafin Generic Name Interferon Alfa-2b Strength 100mg Manufacturer ZYDUS CADILA
Description
Description
Virafin 80mg Injection consists of the active interferon alfa-2b. It treats various diseases, including cancers and viral infections (chronic hepatitis B, hepatitis C). It is similar to a protein that your body naturally produces called interferon. It modifies the response of the body’s immune system to help fight infections and severe diseases. This medicine helps to suppress viral replication and reduce liver inflammation.
Talk to your doctor if you have any severe heart disease, kidney disorders, liver diseases, history of seizures, autoimmune disorders, thyroid problems, or had an organ transplant before taking virafin 80mg Injection. Administration of this medicine may lead to dental and gum disorders. You should drink extra fluids to help prevent low blood pressure. Patients with a history of autoimmune disorders should be closely monitored for signs and symptoms during treatment.
Date of Approval
The U.S. Food and Drug Administration (FDA) approved peginterferon alfa-2b (PEG-IFN) on March 29, 2011. The brand name for PEG-IFN is Sylatron.
Mechanism of Action of Interferon Alfa-2b
Uses of Interferon Alfa-2b
- Chronic myelogenous leukemia
- Hairy cell leukemia
- Malignant melanoma
- Follicular lymphoma
- Multiple myeloma
- Carcinoid tumor
- Viral infections such as chronic hepatitis B or C
Interferon Alfa-2b Dosage available
Virafin 80mg Injection is typically administered through injection by a healthcare provider. The specific method of administration may vary depending on the condition being treated and the healthcare provider’s instructions. If a dose is missed, the patient should contact their healthcare provider for further instructions.